Recent insights on the role of cholesterol in non-alcoholic fatty liver disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 9, 2015, Pages 1765-1778

  Arguello, Graciela ^a,b   Balboa, Elisa ^a   Arrese, Marco ^a   Zanlungo, Silvana ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b FONDAP   (Chile)

Author keywords

Cholesterol homeostasis; Free cholesterol; Lipotoxicity; Liver; NAFLD; NASH

Indexed keywords

CHOLESTEROL; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; HYPOCHOLESTEROLEMIC AGENT; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

CELL ACTIVATION; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DISEASE ACTIVITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HOMEOSTASIS; HUMAN; INTRACELLULAR TRANSPORT; KUPFFER CELL; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; STELLATE CELL; UNFOLDED PROTEIN RESPONSE;

EID: 84930632138     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.05.015     Document Type: Review

References (266)

1. Lomonaco R., Sunny N.E., Bril F., Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 2013, 73:1-14.
2. Brunt E.M. Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:195-203.
3. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011, 34:274-285.
4. Riquelme A., Arrese M., Soza A., Morales A., Baudrand R., Perez-Ayuso R.M., Gonzalez R., Alvarez M., Hernandez V., Garcia-Zattera M.J., Otarola F., Medina B., Rigotti A., Miquel J.F., Marshall G., Nervi F. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2009, 29:82-88.
5. Boza C., Riquelme A., Ibanez L., Duarte I., Norero E., Viviani P., Soza A., Fernandez J.I., Raddatz A., Guzman S., Arrese M. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes. Surg. 2005, 15:1148-1153.
6. Machado M.V., Goncalves S., Carepa F., Coutinho J., Costa A., Cortez-Pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 2012, 32:241-248.
7. Rahimi R.S., Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr. Clin. Pract. 2013, 28:40-51.
8. Targher G., Byrne C.D. A perspective on metabolic syndrome and nonalcoholic fatty liver disease. Metab. Syndr. Relat. Disord. 2015.
9. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:330-344.
10. Charlton M.R., Burns J.M., Pedersen R.A., Watt K.D., Heimbach J.K., Dierkhising R.A. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141:1249-1253.
11. Byrne C.D., Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015, 62:S47-S64.
12. Marra F., Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr. Pharm. Des. 2013, 19:5250-5269.
13. Nguyen T.A., Sanyal A.J. Pathophysiology guided treatment of nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2012, 27(Suppl. 2):58-64.
14. Ratziu V., Goodman Z., Sanyal A. Current efforts and trends in the treatment of NASH. J. Hepatol. 2015, 62:S65-S75.
15. Bashiri A., Tavallaee G., Li L., Ng D.S. Emerging role of cellular cholesterol in the pathogenesis of nonalcoholic fatty liver disease. Curr. Opin. Lipidol. 2013, 24:275-276.
16. Musso G., Gambino R., Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid Res. 2013, 52:175-191.
17. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
18. Lade A., Noon L.A., Friedman S.L. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr. Opin. Oncol. 2014, 26:100-107.
19. Angulo P., Machado M.V., Diehl A.M. Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications. Semin. Liver Dis. 2015, 35:132-145.
20. Duwaerts C.C., Maher J.J. Mechanisms of liver injury in non-alcoholic steatohepatitis. Curr. Hepatol. Rep. 2014, 13:119-129.
21. Trauner M., Arrese M., Wagner M. Fatty liver and lipotoxicity. Biochim. Biophys. Acta 2010, 1801:299-310.
22. Mendez-Sanchez N., Arrese M., Zamora-Valdes D., Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 2007, 27:423-433.
23. Gariani K., Philippe J., Jornayvaz F.R. Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. Diabetes Metab. 2013, 39:16-26.
24. Asrih M., Jornayvaz F.R. Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link?. Mol. Cell. Endocrinol. 2015, in press [Epub ahead of print].
25. Borai A., Livingstone C., Kaddam I., Ferns G. Selection of the appropriate method for the assessment of insulin resistance. BMC Med. Res. Methodol. 2011, 11:158.
26. Birkenfeld A.L., Shulman G.I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014, 59:713-723.
27. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl. 2006, 12:523-534.
28. Byrne C.D. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet. Med. 2012, 29:1098-1107.
29. Wang D.Q., Portincasa P., Neuschwander-Tetri B.A. Steatosis in the liver. Compr. Physiol. 2013, 3:1493-1532.
30. Kolditz C.I., Langin D. Adipose tissue lipolysis. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:377-381.
31. Nielsen T.S., Jessen N., Jorgensen J.O., Moller N., Lund S. Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. J. Mol. Endocrinol. 2014, 52:R199-R222.
32. Fruhbeck G., Mendez-Gimenez L., Fernandez-Formoso J.A., Fernandez S., Rodriguez A. Regulation of adipocyte lipolysis. Nutr. Res. Rev. 2014, 27:63-93.
33. Bluher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27:163-177.
34. Sell H., Habich C., Eckel J. Adaptive immunity in obesity and insulin resistance. Nat. Rev. Endocrinol. 2012, 8:709-716.
35. Eguchi A., Feldstein A.E. Adipocyte cell death, fatty liver disease and associated metabolic disorders. Dig. Dis. 2014, 32:579-585.
36. Tamura S., Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1139-1142.
37. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
38. Doege H., Baillie R.A., Ortegon A.M., Tsang B., Wu Q., Punreddy S., Hirsch D., Watson N., Gimeno R.E., Stahl A. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 2006, 130:1245-1258.
39. Miquilena-Colina M.E., Lima-Cabello E., Sanchez-Campos S., Garcia-Mediavilla M.V., Fernandez-Bermejo M., Lozano-Rodriguez T., Vargas-Castrillon J., Buque X., Ochoa B., Aspichueta P., Gonzalez-Gallego J., Garcia-Monzon C. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 2011, 60:1394-1402.
40. He J., Lee J.H., Febbraio M., Xie W. The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp. Biol. Med. (Maywood) 2011, 236:1116-1121.
41. Newberry E.P., Xie Y., Kennedy S.M., Luo J., Davidson N.O. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 2006, 44:1191-1205.
42. Sanders F.W., Griffin J.L. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol. Rev. Camb. Philos. Soc. 2015, in press [Epub ahead of print].
43. Lambert J.E., Ramos-Roman M.A., Browning J.D., Parks E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014, 146:726-735.
44. Ferre P., Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 2010, 12(Suppl. 2):83-92.
45. Vos M.B., Lavine J.E. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 2013, 57:2525-2531.
46. Chung M., Ma J., Patel K., Berger S., Lau J., Lichtenstein A.H. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am. J. Clin. Nutr. 2014, 100:833-849.
47. Chiu S., Sievenpiper J.L., de Souza R.J., Cozma A.I., Mirrahimi A., Carleton A.J., Ha V., Di Buono M., Jenkins A.L., Leiter L.A., Wolever T.M., Don-Wauchope A.C., Beyene J., Kendall C.W., Jenkins D.J. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur. J. Clin. Nutr. 2014, 68:416-423.
48. Koo S.H. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin. Mol. Hepatol. 2013, 19:210-215.
49. Fabbrini E., Mohammed B.S., Magkos F., Korenblat K.M., Patterson B.W., Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008, 134:424-431.
50. Schuppan D., Schattenberg J.M. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J. Gastroenterol. Hepatol. 2013, 28(Suppl. 1):68-76.
51. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
52. Peverill W., Powell L.W., Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int. J. Mol. Sci. 2014, 15:8591-8638.
53. Hirsova P., Gores G.J. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol. Gastroenterol. Hepatol. 2015, 1:17-27.
54. Fielding C.M., Angulo P. Hepatic steatosis and steatohepatitis: are they really two distinct entities?. Curr. Hepatol. Rep. 2014, 13:151-158.
55. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?. Aliment. Pharmacol. Ther. 2012, 36:815-823.
56. Arrese M. Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease. Hepatology 2009, 49:348-351.
57. Than N.N., Newsome P.N. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015, 239:192-202.
58. Dyson J.K., Anstee Q.M., McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Front. Gastrointest. 2014, 5:277-286.
59. Anstee Q.M., Day C.P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:645-655.
60. Krawczyk M., Portincasa P., Lammert F. PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease. Semin. Liver Dis. 2013, 33:369-379.
61. Liu Y.L., Reeves H.L., Burt A.D., Tiniakos D., McPherson S., Leathart J.B., Allison M.E., Alexander G.J., Piguet A.C., Anty R., Donaldson P., Aithal G.P., Francque S., Van Gaal L., Clement K., Ratziu V., Dufour J.F., Day C.P., Daly A.K., Anstee Q.M. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat. Commun. 2014, 5:4309.
62. Meli R., Mattace Raso G., Calignano A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front. Immunol. 2014, 5:177.
63. Kubes P., Mehal W.Z. Sterile inflammation in the liver. Gastroenterology 2012, 143:1158-1172.
64. Boursier J., Diehl A.M. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog. 2015, 11:e1004559.
65. Miura K., Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J. Gastroenterol. 2014, 20:7381-7391.
66. Miura K., Yang L., van Rooijen N., Brenner D.A., Ohnishi H., Seki E. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 2013, 57:577-589.
67. Wree A., McGeough M.D., Pena C.A., Schlattjan M., Li H., Inzaugarat M.E., Messer K., Canbay A., Hoffman H.M., Feldstein A.E. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J. Mol. Med. (Berl.) 2014, in press [Epub ahead of print].
68. Mehal W.Z. The inflammasome in liver injury and non-alcoholic fatty liver disease. Dig. Dis. 2014, 32:507-515.
69. Puche J.E., Saiman Y., Friedman S.L. Hepatic stellate cells and liver fibrosis. Compr. Physiol. 2013, 3:1473-1492.
70. Lee Y.A., Wallace M.C., Friedman S.L. Pathobiology of liver fibrosis: a translational success story. Gut 2015, 64:830-841.
71. Goh G.B., Pagadala M., Dasarathy J., Arida A.U., Sargent R., Hawkins C., Sourianarayanane A., Khiyami A., Yerian L., Pai R., McCullough A., Dasarathy S. Renin angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int. 2014, 35:979-985.
72. Bataller R., Rombouts K., Altamirano J., Marra F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 2011, 25:231-244.
73. Pawlak M., Lefebvre P., Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 2015, 62:720-733.
74. Friedman S.L. Liver fibrosis in 2012: convergent pathways that cause hepatic fibrosis in NASH. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:71-72.
75. Wallace M.C., Friedman S.L., Mann D.A. Emerging and disease-specific mechanisms of hepatic stellate cell activation. Semin. Liver Dis. 2015, 35:107-118.
76. Trautwein C., Friedman S.L., Schuppan D., Pinzani M. Hepatic fibrosis: concept to treatment. J. Hepatol. 2015, 62:S15-S24.
77. Goldberg I.J., Ginsberg H.N. Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology 2006, 130:1343-1346.
78. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J. Clin. Invest. 2008, 118:829-838.
79. Oude Elferink R.P., Groen A.K. Mechanisms of biliary lipid secretion and their role in lipid homeostasis. Semin. Liver Dis. 2000, 20:293-305.
80. Yamaguchi K., Yang L., McCall S., Huang J., Yu X.X., Pandey S.K., Bhanot S., Monia B.P., Li Y.X., Diehl A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
81. Peretti N., Sassolas A., Roy C.C., Deslandres C., Charcosset M., Castagnetti J., Pugnet-Chardon L., Moulin P., Labarge S., Bouthillier L., Lachaux A., Levy E. Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers. Orphanet J. Rare Dis. 2010, 5:24.
82. McClain C.J., Barve S., Deaciuc I. Good fat/bad fat. Hepatology 2007, 45:1343-1346.
83. Listenberger L.L., Han X., Lewis S.E., Cases S., Farese R.V., Ory D.S., Schaffer J.E. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3077-3082.
84. Cheung O., Sanyal A.J. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Semin. Liver Dis. 2008, 28:351-359.
85. Alkhouri N., Dixon L.J., Feldstein A.E. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 2009, 3:445-451.
86. Pagadala M., Kasumov T., McCullough A.J., Zein N.N., Kirwan J.P. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol. Metab. 2012, 23:365-371.
87. Kurek K., Piotrowska D.M., Wiesiolek-Kurek P., Lukaszuk B., Chabowski A., Gorski J., Zendzian-Piotrowska M. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int. 2014, 34:1074-1083.
88. Brown M.V., Compton S.A., Milburn M.V., Lawton K.A., Cheatham B. Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progression. Obesity 2013, 21:E561-E570.
89. Brenner C., Galluzzi L., Kepp O., Kroemer G. Decoding cell death signals in liver inflammation. J. Hepatol. 2013, 59:583-594.
90. Min H.K., Kapoor A., Fuchs M., Mirshahi F., Zhou H., Maher J., Kellum J., Warnick R., Contos M.J., Sanyal A.J. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012, 15:665-674.
91. Wenfeng Z., Yakun W., Di M., Jianping G., Chuanxin W., Chun H. Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. Ann. Hepatol. 2014, 13:489-495.
92. Puri P., Baillie R.A., Wiest M.M., Mirshahi F., Choudhury J., Cheung O., Sargeant C., Contos M.J., Sanyal A.J. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
93. Neuschwander-Tetri B.A., Wang D.Q. Excess cholesterol and fat in the diet: a dangerous liaison for energy expenditure and the liver. Hepatology 2013, 57:7-9.
94. Caballero F., Fernandez A., De Lacy A.M., Fernandez-Checa J.C., Caballeria J., Garcia-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J. Hepatol. 2009, 50:789-796.
95. Mari M., Caballero F., Colell A., Morales A., Caballeria J., Fernandez A., Enrich C., Fernandez-Checa J.C., Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006, 4:185-198.
96. Tomita K., Teratani T., Suzuki T., Shimizu M., Sato H., Narimatsu K., Okada Y., Kurihara C., Irie R., Yokoyama H., Shimamura K., Usui S., Ebinuma H., Saito H., Watanabe C., Komoto S., Kawaguchi A., Nagao S., Sugiyama K., Hokari R., Kanai T., Miura S., Hibi T. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014, 59:154-169.
97. Savard C., Tartaglione E.V., Kuver R., Haigh W.G., Farrell G.C., Subramanian S., Chait A., Yeh M.M., Quinn L.S., Ioannou G.N. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013, 57:81-92.
98. Van Rooyen D.M., Larter C.Z., Haigh W.G., Yeh M.M., Ioannou G., Kuver R., Lee S.P., Teoh N.C., Farrell G.C. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011, 141:1393-1403. 1403 e1391-1395.
99. Van Rooyen D.M., Gan L.T., Yeh M.M., Haigh W.G., Larter C.Z., Ioannou G., Teoh N.C., Farrell G.C. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J. Hepatol. 2013, 59:144-152.
100. Mells J.E., Fu P.P., Kumar P., Smith T., Karpen S.J., Anania F.A. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J. Nutr. Biochem. 2015, 26:285-292.
101. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., Faga E., Silli B., Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37:909-916.
102. Yasutake K., Nakamuta M., Shima Y., Ohyama A., Masuda K., Haruta N., Fujino T., Aoyagi Y., Fukuizumi K., Yoshimoto T., Takemoto R., Miyahara T., Harada N., Hayata F., Nakashima M., Enjoji M. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand. J. Gastroenterol. 2009, 44:471-477.
103. Enjoji M., Nakamuta M. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?. World J. Gastroenterol. 2010, 16:800-803.
104. Wouters K., van Bilsen M., van Gorp P.J., Bieghs V., Lutjohann D., Kerksiek A., Staels B., Hofker M.H., Shiri-Sverdlov R. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. 2010, 584:1001-1005.
105. Zhao L., Chen Y., Tang R., Chen Y., Li Q., Gong J., Huang A., Varghese Z., Moorhead J.F., Ruan X.Z. Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis. J. Gastroenterol. Hepatol. 2011, 26:875-883.
106. Deushi M., Nomura M., Kawakami A., Haraguchi M., Ito M., Okazaki M., Ishii H., Yoshida M. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007, 581:5664-5670.
107. Zheng S., Hoos L., Cook J., Tetzloff G., Davis H., van Heek M., Hwa J.J. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur. J. Pharmacol. 2008, 584:118-124.
108. Nozaki Y., Fujita K., Yoneda M., Wada K., Shinohara Y., Takahashi H., Kirikoshi H., Inamori M., Kubota K., Saito S., Mizoue T., Masaki N., Nagashima Y., Terauchi Y., Nakajima A. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J. Hepatol. 2009, 51:548-556.
109. Averna M. The effect of ezetimibe on NAFLD. Atherosclerosis 2015, 17:27-34. (Supplements).
110. Musso G., Cassader M., Gambino R. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr. Opin. Lipidol. 2011, 22:489-496.
111. D.J., Turley S. The metabolism and excretion of cholesterol by the liver. The Liver: Biology and Pathobiology, New York 1998, 617-641. J.W., I.M. Arias, H. Popper, D. Schachter, D.A. Shafritz (Eds.).
112. Cohen D. Lipoprotein metabolism and cholesterol balance. Biology and Pathobiology, Oxford 2009, 271-285. I.A., H. Arias, J.L. Boyer, D.E. Cohen, N. Fausto, D.A. Shafritz, A.W. Wolkoff (Eds.).
113. Cortes V.A., Busso D., Maiz A., Arteaga A., Nervi F., Rigotti A. Physiological and pathological implications of cholesterol. Front. Biosci. (Landmark Ed.) 2014, 19:416-428.
114. Mesmin B., Antonny B., Drin G. Insights into the mechanisms of sterol transport between organelles. Cell. Mol. Life Sci. 2013, 70:3405-3421.
115. Zanlungo S., Rigotti A. Determinants of transhepatic cholesterol flux and their relevance for gallstone formation. Liver Int. 2009, 29:323-330.
116. Luu W., Sharpe L.J., Gelissen I.C., Brown A.J. The role of signalling in cellular cholesterol homeostasis. IUBMB Life 2013, 65:675-684.
117. Kalaany N.Y., Mangelsdorf D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 2006, 68:159-191.
118. Anderson R.G. Joe Goldstein and Mike Brown: from cholesterol homeostasis to new paradigms in membrane biology. Trends Cell Biol. 2003, 13:534-539.
119. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., Willson T.M., Zavacki A.M., Moore D.D., Lehmann J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
120. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., Shan B. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
121. Wang H., Chen J., Hollister K., Sowers L.C., Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3:543-553.
122. Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., Galardi C., Wilson J.G., Lewis M.C., Roth M.E., Maloney P.R., Willson T.M., Kliewer S.A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 2000, 6:517-526.
123. Xu J.Y., Li Z.P., Zhang L., Ji G. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20:13493-13500.
124. Chiang J.Y., Kimmel R., Weinberger C., Stroup D. Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. 2000, 275:10918-10924.
125. Fuchs M., Ivandic B., Muller O., Schalla C., Scheibner J., Bartsch P., Stange E.F. Biliary cholesterol hypersecretion in gallstone-susceptible mice is associated with hepatic up-regulation of the high-density lipoprotein receptor SRBI. Hepatology 2001, 33:1451-1459.
126. Zhao B., Song J., Ghosh S. Hepatic overexpression of cholesteryl ester hydrolase enhances cholesterol elimination and in vivo reverse cholesterol transport. J. Lipid Res. 2008, 49:2212-2217.
127. Fuchs M., Lammert F., Wang D.Q., Paigen B., Carey M.C., Cohen D.E. Sterol carrier protein 2 participates in hypersecretion of biliary cholesterol during gallstone formation in genetically gallstone-susceptible mice. Biochem. J. 1998, 336(Pt 1):33-37.
128. Lu K., Lee M.H., Hazard S., Brooks-Wilson A., Hidaka H., Kojima H., Ose L., Stalenhoef A.F., Mietinnen T., Bjorkhem I., Bruckert E., Pandya A., Brewer H.B., Salen G., Dean M., Srivastava A., Patel S.B. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am. J. Hum. Genet. 2001, 69:278-290.
129. Lambert G., Amar M.J., Guo G., Brewer H.B., Gonzalez F.J., Sinal C.J. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 2003, 278:2563-2570.
130. Zhao C., Dahlman-Wright K. Liver X receptor in cholesterol metabolism. J. Endocrinol. 2010, 204:233-240.
131. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
132. Calkin A.C., Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 2012, 13:213-224.
133. Cicione C., Degirolamo C., Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology 2012, 56:2404-2411.
134. Potthoff M.J., Boney-Montoya J., Choi M., He T., Sunny N.E., Satapati S., Suino-Powell K., Xu H.E., Gerard R.D., Finck B.N., Burgess S.C., Mangelsdorf D.J., Kliewer S.A. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab. 2011, 13:729-738.
135. Reue K., Lee J.M., Vergnes L. Regulation of bile acid homeostasis by the intestinal Diet1-FGF15/19 axis. Curr. Opin. Lipidol. 2014, 25:140-147.
136. Simonen P., Kotronen A., Hallikainen M., Sevastianova K., Makkonen J., Hakkarainen A., Lundbom N., Miettinen T.A., Gylling H., Yki-Jarvinen H. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J. Hepatol. 2011, 54:153-159.
137. Beg Z.H., Stonik J.A., Brewer H.B. Phosphorylation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and modulation of its enzymic activity by calcium-activated and phospholipid-dependent protein kinase. J. Biol. Chem. 1985, 260:1682-1687.
138. Beg Z.H., Stonik J.A., Brewer H.B. Modulation of the enzymic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase systems involving reversible phosphorylation: a review. Metab. Clin. Exp. 1987, 36:900-917.
139. Fon Tacer K., Rozman D. Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. J. Lipid 2011, 2011:783976.
140. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 2009, 48:1-26.
141. Cohen D.E., Fisher E.A. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin. Liver Dis. 2013, 33:380-388.
142. Corey K.E., Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2014, 12:1077-1084. (quiz e1059-1060).
143. Siddiqui M.S., Fuchs M., Idowu M.O., Luketic V.A., Boyett S., Sargeant C., Stravitz R.T., Puri P., Matherly S., Sterling R.K., Contos M., Sanyal A.J. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin. Gastroenterol. Hepatol. 2015, 13:1000-e1008. (e1003).
144. Yang Y., Jiang Y., Wang Y., An W. Suppression of ABCA1 by unsaturated fatty acids leads to lipid accumulation in HepG2 cells. Biochimie 2010, 92:958-963.
145. Ma D., Liu W., Wang Y. ApoA-I or ABCA1 expression suppresses fatty acid synthesis by reducing 27-hydroxycholesterol levels. Biochimie 2014, 103:101-108.
146. Su K., Sabeva N.S., Liu J., Wang Y., Bhatnagar S., van der Westhuyzen D.R., Graf G.A. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation. J. Biol. Chem. 2012, 287:28564-28575.
147. Pizarro M., Balasubramaniyan N., Solis N., Solar A., Duarte I., Miquel J.F., Suchy F.J., Trauner M., Accatino L., Ananthanarayanan M., Arrese M. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut 2004, 53:1837-1843.
148. Tran K.Q., Graewin S.J., Swartz-Basile D.A., Nakeeb A., Svatek C.L., Pitt H.A. Leptin-resistant obese mice have paradoxically low biliary cholesterol saturation. Surgery 2003, 134:372-377.
149. Su K., Sabeva N.S., Wang Y., Liu X., Lester J.D., Liu J., Liang S., Graf G.A. Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice. Arterioscler. Thromb. Vasc. Biol. 2014, 34:26-33.
150. Biddinger S.B., Haas J.T., Yu B.B., Bezy O., Jing E., Zhang W., Unterman T.G., Carey M.C., Kahn C.R. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat. Med. 2008, 14:778-782.
151. Loria P., Lonardo A., Lombardini S., Carulli L., Verrone A., Ganazzi D., Rudilosso A., D'Amico R., Bertolotti M., Carulli N. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J. Gastroenterol. Hepatol. 2005, 20:1176-1184.
152. Ahmed M.H., Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first?. Scand. J. Gastroenterol. 2014, 49:521-527.
153. Spolding B., Connor T., Wittmer C., Abreu L.L., Kaspi A., Ziemann M., Kaur G., Cooper A., Morrison S., Lee S., Sinclair A., Gibert Y., Trevaskis J.L., Roth J.D., El-Osta A., Standish R., Walder K. Rapid development of non-alcoholic steatohepatitis in Psammomys obesus (Israeli sand rat). PLoS One 2014, 9:e92656.
154. Li T., Kong X., Owsley E., Ellis E., Strom S., Chiang J.Y. Insulin regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes: roles of forkhead box O1 and sterol regulatory element-binding protein 1c. J. Biol. Chem. 2006, 281:28745-28754.
155. de Bari O., Neuschwander-Tetri B.A., Liu M., Portincasa P., Wang D.Q. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. J. Lipid 2012, 2012:302847.
156. Sanyal A.J., Friedman S.L., McCullough A.J., Dimick L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases (AASLD) - Food and Drug Administration (FDA) joint workshop. Hepatology 2015, 61:1392-1405.
157. Li S., Chen X., Zhang H., Liang X., Xiang Y., Yu C., Zen K., Li Y., Zhang C.Y. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J. Lipid Res. 2009, 50:1756-1765.
158. Cheung O., Puri P., Eicken C., Contos M.J., Mirshahi F., Maher J.W., Kellum J.M., Min H., Luketic V.A., Sanyal A.J. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008, 48:1810-1820.
159. Jin X., Ye Y.F., Chen S.H., Yu C.H., Liu J., Li Y.M. MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig. Liver Dis. 2009, 41:289-297.
160. Gori M., Arciello M. MicroRNAs in Nonalcoholic Fatty Liver Disease: Novel Biomarkers and Prognostic Tools During the Transition From Steatosis to Hepatocarcinoma, 2014 2014, 741465.
161. Arrese M., Eguchi A., Feldstein A.E. Circulating microRNAs: emerging biomarkers of liver disease. Semin. Liver Dis. 2015, 35:43-54.
162. Kerr T.A., Davidson N.O. Cholesterol and nonalcoholic fatty liver disease: renewed focus on an old villain. Hepatology 2012, 56:1995-1998.
163. Pogribny I.P., Starlard-Davenport A., Tryndyak V.P., Han T., Ross S.A., Rusyn I., Beland F.A. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab. Invest. 2010, 90:1437-1446.
164. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
165. Esau C., Davis S., Murray S.F., Yu X.X., Pandey S.K., Pear M., Watts L., Booten S.L., Graham M., McKay R., Subramaniam A., Propp S., Lollo B.A., Freier S., Bennett C.F., Bhanot S., Monia B.P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3:87-98.
166. Sun C., Huang F., Liu X., Xiao X., Yang M., Hu G., Liu H., Liao L. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int. J. Mol. Med. 2015, 35:847-853.
167. Fielding C.J., Fielding P.E. Caveolae and intracellular trafficking of cholesterol. Adv. Drug Deliv. Rev. 2001, 49:251-264.
168. Mastrodonato M., Calamita G., Rossi R., Mentino D., Bonfrate L., Portincasa P., Ferri D., Liquori G.E. Altered distribution of caveolin-1 in early liver steatosis. Eur. J. Clin. Investig. 2011, 41:642-651.
169. Qiu Y., Liu S., Chen H.T., Yu C.H., Teng X.D., Yao H.T., Xu G.Q. Upregulation of caveolin-1 and SR-B1 in mice with non-alcoholic fatty liver disease. Hepatobiliary Pancreat. Dis. Int. 2013, 12:630-636.
170. Klein A.D., Alvarez A., Zanlungo S. The unique case of the Niemann-Pick type C cholesterol storage disorder. Pediatr. Endocrinol. Rev. 2014, 12(Suppl. 1):166-175.
171. Vanier M.T. Complex lipid trafficking in Niemann-Pick disease type C. J. Inherit. Metab. Dis. 2015, 38:187-199.
172. Jelinek D., Heidenreich R.A., Erickson R.P., Garver W.S. Decreased Npc1 gene dosage in mice is associated with weight gain. Obesity 2010, 18:1457-1459.
173. Jelinek D., Millward V., Birdi A., Trouard T.P., Heidenreich R.A., Garver W.S. Npc1 haploinsufficiency promotes weight gain and metabolic features associated with insulin resistance. Hum. Mol. Genet. 2011, 20:312-321.
174. Meyre D., Delplanque J., Chevre J.C., Lecoeur C., Lobbens S., Gallina S., Durand E., Vatin V., Degraeve F., Proenca C., Gaget S., Korner A., Kovacs P., Kiess W., Tichet J., Marre M., Hartikainen A.L., Horber F., Potoczna N., Hercberg S., Levy-Marchal C., Pattou F., Heude B., Tauber M., McCarthy M.I., Blakemore A.I., Montpetit A., Polychronakos C., Weill J., Coin L.J., Asher J., Elliott P., Jarvelin M.R., Visvikis-Siest S., Balkau B., Sladek R., Balding D., Walley A., Dina C., Froguel P. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat. Genet. 2009, 41:157-159.
175. Robiou-du-Pont S., Bonnefond A., Yengo L., Vaillant E., Lobbens S., Durand E., Weill J., Lantieri O., Balkau B., Charpentier G., Marre M., Froguel P., Meyre D. Contribution of 24 obesity-associated genetic variants to insulin resistance, pancreatic beta-cell function and type 2 diabetes risk in the French population. Int. J. Obes. 2013, 37:980-985.
176. Soccio R.E., Breslow J.L. StAR-related lipid transfer (START) proteins: mediators of intracellular lipid metabolism. J. Biol. Chem. 2003, 278:22183-22186.
177. Stocco D.M. The role of the StAR protein in steroidogenesis: challenges for the future. J. Endocrinol. 2000, 164:247-253.
178. Watari H., Arakane F., Moog-Lutz C., Kallen C.B., Tomasetto C., Gerton G.L., Rio M.C., Baker M.E., Strauss J.F. MLN64 contains a domain with homology to the steroidogenic acute regulatory protein (StAR) that stimulates steroidogenesis. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:8462-8467.
179. Alpy F., Stoeckel M.E., Dierich A., Escola J.M., Wendling C., Chenard M.P., Vanier M.T., Gruenberg J., Tomasetto C., Rio M.C. The steroidogenic acute regulatory protein homolog MLN64, a late endosomal cholesterol-binding protein. J. Biol. Chem. 2001, 276:4261-4269.
180. Calderon-Dominguez M., Gil G., Medina M.A., Pandak W.M., Rodriguez-Agudo D. The StarD4 subfamily of steroidogenic acute regulatory-related lipid transfer (START) domain proteins: new players in cholesterol metabolism. Int. J. Biochem. Cell Biol. 2014, 49:64-68.
181. Olkkonen V.M., Beaslas O., Nissila E. Oxysterols and their cellular effectors. Biomolecules 2012, 2:76-103.
182. Olkkonen V.M. OSBP-related proteins: liganding by glycerophospholipids opens new insight into their function. Molecules 2013, 18:13666-13679.
183. Yan D., Mayranpaa M.I., Wong J., Perttila J., Lehto M., Jauhiainen M., Kovanen P.T., Ehnholm C., Brown A.J., Olkkonen V.M. OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages. J. Biol. Chem. 2008, 283:332-340.
184. Zhou T., Li S., Zhong W., Vihervaara T., Beaslas O., Perttila J., Luo W., Jiang Y., Lehto M., Olkkonen V.M., Yan D. OSBP-related protein 8 (ORP8) regulates plasma and liver tissue lipid levels and interacts with the nucleoporin Nup62. PLoS One 2011, 6:e21078.
185. Jordan S.D., Kruger M., Willmes D.M., Redemann N., Wunderlich F.T., Bronneke H.S., Merkwirth C., Kashkar H., Olkkonen V.M., Bottger T., Braun T., Seibler J., Bruning J.C. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat. Cell Biol. 2011, 13:434-446.
186. Gan L.T., Van Rooyen D.M., Koina M.E., McCuskey R.S., Teoh N.C., Farrell G.C. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J. Hepatol. 2014, 61:1376-1384.
187. Smedsrod B., De Bleser P.J., Braet F., Lovisetti P., Vanderkerken K., Wisse E., Geerts A. Cell biology of liver endothelial and Kupffer cells. Gut 1994, 35:1509-1516.
188. Meijer C., Wiezer M.J., Diehl A.M., Schouten H.J., Schouten H.J., Meijer S., van Rooijen N., van Lambalgen A.A., Dijkstra C.D., van Leeuwen P.A. Kupffer cell depletion by CI2MDP-liposomes alters hepatic cytokine expression and delays liver regeneration after partial hepatectomy. Liver 2000, 20:66-77.
189. Rai R.M., Loffreda S., Karp C.L., Yang S.Q., Lin H.Z., Diehl A.M. Kupffer cell depletion abolishes induction of interleukin-10 and permits sustained overexpression of tumor necrosis factor alpha messenger RNA in the regenerating rat liver. Hepatology 1997, 25:889-895.
190. Ono M., Saibara T. Is impaired Kupffer cell function really important to the pathogenesis of nonalcoholic steatohepatitis?. J. Gastroenterol. Hepatol. 2012, 27:622-624.
191. Bieghs V., Verheyen F., van Gorp P.J., Hendrikx T., Wouters K., Lutjohann D., Gijbels M.J., Febbraio M., Binder C.J., Hofker M.H., Shiri-Sverdlov R. Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells. PLoS One 2012, 7:e34378.
192. Leroux A., Ferrere G., Godie V., Cailleux F., Renoud M.L., Gaudin F., Naveau S., Prevot S., Makhzami S., Perlemuter G., Cassard-Doulcier A.M. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J. Hepatol. 2012, 57:141-149.
193. Wouters K., van Gorp P.J., Bieghs V., Gijbels M.J., Duimel H., Lutjohann D., Kerksiek A., van Kruchten R., Maeda N., Staels B., van Bilsen M., Shiri-Sverdlov R., Hofker M.H. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008, 48:474-486.
194. Ioannou G.N., Haigh W.G., Thorning D., Savard C. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J. Lipid Res. 2013, 54:1326-1334.
195. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., Abela G.S., Franchi L., Nunez G., Schnurr M., Espevik T., Lien E., Fitzgerald K.A., Rock K.L., Moore K.J., Wright S.D., Hornung V., Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
196. Rajamaki K., Lappalainen J., Oorni K., Valimaki E., Matikainen S., Kovanen P.T., Eklund K.K. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
197. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 2008, 88:125-172.
198. Carotti S., Morini S., Corradini S.G., Burza M.A., Molinaro A., Carpino G., Merli M., De Santis A., Muda A.O., Rossi M., Attili A.F., Gaudio E. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl. 2008, 14:806-814.
199. Carpino G., Franchitto A., Morini S., Corradini S.G., Merli M., Gaudio E. Activated hepatic stellate cells in liver cirrhosis. A morphologic and morphometrical study. Ital. J. Anat. Embryol. 2004, 109:225-238.
200. Teratani T., Tomita K., Suzuki T., Oshikawa T., Yokoyama H., Shimamura K., Tominaga S., Hiroi S., Irie R., Okada Y., Kurihara C., Ebinuma H., Saito H., Hokari R., Sugiyama K., Kanai T., Miura S., Hibi T. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 2012, 142:152-e164. (e110).
201. Tomita K., Teratani T., Suzuki T., Shimizu M., Sato H., Narimatsu K., Usui S., Furuhashi H., Kimura A., Nishiyama K., Maejima T., Okada Y., Kurihara C., Shimamura K., Ebinuma H., Saito H., Yokoyama H., Watanabe C., Komoto S., Nagao S., Sugiyama K., Aosasa S., Hatsuse K., Yamamoto J., Hibi T., Miura S., Hokari R., Kanai T. Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells. J. Hepatol. 2014, 61:98-106.
202. Lee A.S. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem. Sci. 2001, 26:504-510.
203. Song Y., Jiang Y., Ying W., Gong Y., Yan Y., Yang D., Ma J., Xue X., Zhong F., Wu S., Hao Y., Sun A., Li T., Sun W., Wei H., Zhu Y., Qian X., He F. Quantitative proteomic survey of endoplasmic reticulum in mouse liver. J. Proteome Res. 2010, 9:1195-1202.
204. Fu S., Watkins S.M., Hotamisligil G.S. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab. 2012, 15:623-634.
205. Kaufman R.J. Orchestrating the unfolded protein response in health and disease. J. Clin. Invest. 2002, 110:1389-1398.
206. Ron D. Translational control in the endoplasmic reticulum stress response. J. Clin. Invest. 2002, 110:1383-1388.
207. Walter P., Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011, 334:1081-1086.
208. Mori K. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 2000, 101:451-454.
209. Hampton R.Y. ER stress response: getting the UPR hand on misfolded proteins. Curr. Biol. 2000, 10:R518-R521.
210. Gentile C.L., Frye M., Pagliassotti M.J. Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxid. Redox Signal. 2011, 15:505-521.
211. Puri P., Mirshahi F., Cheung O., Natarajan R., Maher J.W., Kellum J.M., Sanyal A.J. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008, 134:568-576.
212. Rinella M.E., Siddiqui M.S., Gardikiotes K., Gottstein J., Elias M., Green R.M. Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology 2011, 54:1600-1609.
213. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., Gorgun C.Z., Hotamisligil G.S. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
214. Wang D., Wei Y., Pagliassotti M.J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006, 147:943-951.
215. Ota T., Gayet C., Ginsberg H.N. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J. Clin. Invest. 2008, 118:316-332.
216. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., Tuncman G., Gorgun C., Glimcher L.H., Hotamisligil G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461.
217. Fang D.L., Wan Y., Shen W., Cao J., Sun Z.X., Yu H.H., Zhang Q., Cheng W.H., Chen J., Ning B. Endoplasmic reticulum stress leads to lipid accumulation through upregulation of SREBP-1c in normal hepatic and hepatoma cells. Mol. Cell. Biochem. 2013, 381:127-137.
218. Feng B., Yao P.M., Li Y., Devlin C.M., Zhang D., Harding H.P., Sweeney M., Rong J.X., Kuriakose G., Fisher E.A., Marks A.R., Ron D., Tabas I. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat. Cell Biol. 2003, 5:781-792.
219. Maxfield F.R., Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005, 438:612-621.
220. Hager L., Li L., Pun H., Liu L., Hossain M.A., Maguire G.F., Naples M., Baker C., Magomedova L., Tam J., Adeli K., Cummins C.L., Connelly P.W., Ng D.S. Lecithin:cholesterol acyltransferase deficiency protects against cholesterol-induced hepatic endoplasmic reticulum stress in mice. J. Biol. Chem. 2012, 287:20755-20768.
221. Rohrl C., Eigner K., Winter K., Korbelius M., Obrowsky S., Kratky D., Kovacs W.J., Stangl H. Endoplasmic reticulum stress impairs cholesterol efflux and synthesis in hepatic cells. J. Lipid Res. 2014, 55:94-103.
222. Jovaisaite V., Mouchiroud L., Auwerx J. The mitochondrial unfolded protein response, a conserved stress response pathway with implications in health and disease. J. Exp. Biol. 2014, 217:137-143.
223. Wu Y., Williams E.G., Dubuis S., Mottis A., Jovaisaite V., Houten S.M., Argmann C.A., Faridi P., Wolski W., Kutalik Z., Zamboni N., Auwerx J., Aebersold R. Multilayered genetic and omics dissection of mitochondrial activity in a mouse reference population. Cell 2014, 158:1415-1430.
224. Fernandez-Checa J.C., Kaplowitz N. Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol. Appl. Pharmacol. 2005, 204:263-273.
225. Lluis J.M., Colell A., Garcia-Ruiz C., Kaplowitz N., Fernandez-Checa J.C. Acetaldehyde impairs mitochondrial glutathione transport in HepG2 cells through endoplasmic reticulum stress. Gastroenterology 2003, 124:708-724.
226. Colell A., Garcia-Ruiz C., Lluis J.M., Coll O., Mari M., Fernandez-Checa J.C. Cholesterol impairs the adenine nucleotide translocator-mediated mitochondrial permeability transition through altered membrane fluidity. J. Biol. Chem. 2003, 278:33928-33935.
227. Montero J., Mari M., Colell A., Morales A., Basanez G., Garcia-Ruiz C., Fernandez-Checa J.C. Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death. Biochim. Biophys. Acta 2010, 1797:1217-1224.
228. Campbell A.M., Chan S.H. The voltage dependent anion channel affects mitochondrial cholesterol distribution and function. Arch. Biochem. Biophys. 2007, 466:203-210.
229. Campbell A.M., Chan S.H. Mitochondrial membrane cholesterol, the voltage dependent anion channel (VDAC), and the Warburg effect. J. Bioenerg. Biomembr. 2008, 40:193-197.
230. Yu W., Gong J.S., Ko M., Garver W.S., Yanagisawa K., Michikawa M. Altered cholesterol metabolism in Niemann-Pick type C1 mouse brains affects mitochondrial function. J. Biol. Chem. 2005, 280:11731-11739.
231. Coll O., Colell A., Garcia-Ruiz C., Kaplowitz N., Fernandez-Checa J.C. Sensitivity of the 2-oxoglutarate carrier to alcohol intake contributes to mitochondrial glutathione depletion. Hepatology 2003, 38:692-702.
232. Yin M., Wheeler M.D., Kono H., Bradford B.U., Gallucci R.M., Luster M.I., Thurman R.G. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999, 117:942-952.
233. Marí M., Morales A., Colell A., García-Ruiz C., Fernández-Checa J.C. Mitochondrial cholesterol accumulation in alcoholic liver disease: role of ASMase and endoplasmic reticulum stress. Redox Biology 2014, 3:100-108.
234. Lavigne P., Najmanivich R., Lehoux J.G. Mammalian StAR-related lipid transfer (START) domains with specificity for cholesterol: structural conservation and mechanism of reversible binding. Subcell. Biochem. 2010, 51:425-437.
235. Tichauer J.E., Morales M.G., Amigo L., Galdames L., Klein A., Quinones V., Ferrada C., Alvarez A.R., Rio M.C., Miquel J.F., Rigotti A., Zanlungo S. Overexpression of the cholesterol-binding protein MLN64 induces liver damage in the mouse. World J. Gastroenterol. 2007, 13:3071-3079.
236. Charman M., Kennedy B.E., Osborne N., Karten B. MLN64 mediates egress of cholesterol from endosomes to mitochondria in the absence of functional Niemann-Pick Type C1 protein. J. Lipid Res. 2010, 51:1023-1034.
237. Soffientini U., Caridis A.M., Dolan S., Graham A. Intracellular cholesterol transporters and modulation of hepatic lipid metabolism: implications for diabetic dyslipidaemia and steatosis. Biochim. Biophys. Acta 2014, 1842:1372-1382.
238. Li L., Chen L., Hu L., Liu Y., Sun H.Y., Tang J., Hou Y.J., Chang Y.X., Tu Q.Q., Feng G.S., Shen F., Wu M.C., Wang H.Y. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011, 54:1620-1630.
239. Tziomalos K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World J. Hepatol. 2014, 6:738-744.
240. Pastori D., Polimeni L., Baratta F., Pani A., Del Ben M., Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig. Liver Dis. 2015, 47:4-11.
241. Nseir W., Mahamid M. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. Curr. Atheroscler. Rep. 2013, 15:305.
242. Okada Y., Yamaguchi K., Nakajima T., Nishikawa T., Jo M., Mitsumoto Y., Kimura H., Nishimura T., Tochiki N., Yasui K., Mitsuyoshi H., Minami M., Kagawa K., Okanoue T., Itoh Y. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. Liver Int. 2013, 33:301-311.
243. de Keyser C.E., Koehler E.M., Schouten J.N., Visser L.E., Hofman A., Janssen H.L., Stricker B.H. Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. Dig. Liver Dis. 2014, 46:720-725.
244. Eslami L., Merat S., Malekzadeh R., Nasseri-Moghaddam S., Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst. Rev. 2013, 12:CD008623.
245. Dongiovanni P., Petta S., Mannisto V., Margherita Mancina R., Pipitone R., Karja V., Maggioni M., Kakela P., Wiklund O., Mozzi E., Grimaudo S., Kaminska D., Rametta R., Craxi A., Fargion S., Nobili V., Romeo S., Pihlajamaki J., Valenti L. Statin use and nonalcoholic steatohepatitis in at risk individuals. J. Hepatol. 2015, in press [Epub ahead of print].
246. Katsiki N., Theocharidou E., Karagiannis A., Athyros V.G., Mikhailidis D.P. Ezetimibe therapy for dyslipidemia: an update. Curr. Pharm. Des. 2013, 19:3107-3114.
247. Oishi T., Terai S., Kuwashiro S., Fujisawa K., Matsumoto T., Nishina H., Sakaida I. Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model. Biochem. Biophys. Res. Commun. 2012, 422:22-27.
248. Musso G. Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD?. Diabetologia 2014, 57:850-855.
249. Takeshita Y., Takamura T., Honda M., Kita Y., Zen Y., Kato K., Misu H., Ota T., Nakamura M., Yamada K., Sunagozaka H., Arai K., Yamashita T., Mizukoshi E., Kaneko S. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014, 57:878-890.
250. Loomba R., Sirlin C.B., Ang B., Bettencourt R., Jain R., Salotti J., Soaft L., Hooker J., Kono Y., Bhatt A., Hernandez L., Nguyen P., Noureddin M., Haufe W., Hooker C., Yin M., Ehman R., Lin G.Y., Valasek M.A., Brenner D.A., Richards L. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015, 61:1239-1250. N.R.C. San Diego Integrated.
251. Turley S.D., Daggy B.P., Dietschy J.M. Effect of feeding psyllium and cholestyramine in combination on low density lipoprotein metabolism and fecal bile acid excretion in hamsters with dietary-induced hypercholesterolemia. J. Cardiovasc. Pharmacol. 1996, 27:71-79.
252. Tagawa H., Irie J., Itoh A., Kusumoto Y., Kato M., Kobayashi N., Tanaka K., Morinaga R., Fujita M., Nakajima Y., Morimoto K., Sugizaki T., Kawano Y., Yamada S., Kawai T., Watanabe M., Itoh H. Bile acid binding resin improves hepatic insulin sensitivity by reducing cholesterol but not triglyceride levels in the liver. Diabetes Res. Clin. Pract. 2015, in press [Epub ahead of print].
253. Le T.A., Chen J., Changchien C., Peterson M.R., Kono Y., Patton H., Cohen B.L., Brenner D., Sirlin C., Loomba R. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012, 56:922-932. N.R.C. San Diego Integrated.
254. Solis N., Pizarro M., Quintero P., Arab J.P., Riquelme A., Padilla O., Carrasco G., Pirola C.J., Sookoian S., Arrese M. Effects of bile acid sequestration on hepatic steatosis in obese mice. Ann. Hepatol. 2013, 13:105-112.
255. Arrese M., Karpen S.J. Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. Clin. Pharmacol. Ther. 2010, 87:473-478.
256. Carr R.M., Reid A.E. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr. Atheroscler. Rep. 2015, 17:500.
257. Adorini L., Pruzanski M., Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today 2012, 17:988-997.
258. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., Chalasani N., Dasarathy S., Diehl A.M., Hameed B., Kowdley K.V., McCullough A., Terrault N., Clark J.M., Tonascia J., Brunt E.M., Kleiner D.E., Doo E. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015, 385:956-965.
259. Trauner M., Claudel T., Fickert P., Moustafa T., Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig. Dis. 2010, 28:220-224.
260. Claudel T., Staels B., Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2020-2030.
261. Arrese M., Cabrera D., Barrera F. Obeticholic acid: expanding the therapeutic landscape of NASH. Ann. Hepatol. 2015, 14:430-432.
262. Cable E.E., Finn P.D., Stebbins J.W., Hou J., Ito B.R., van Poelje P.D., Linemeyer D.L., Erion M.D. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009, 49:407-417.
263. Panjwani N., Mulvihill E.E., Longuet C., Yusta B., Campbell J.E., Brown T.J., Streutker C., Holland D., Cao X., Baggio L.L., Drucker D.J. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013, 154:127-139.
264. Parlevliet E.T., Wang Y., Geerling J.J., Schroder-Van der Elst J.P., Picha K., O'Neil K., Stojanovic-Susulic V., Ort T., Havekes L.M., Romijn J.A., Pijl H., Rensen P.C. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One 2012, 7:e49152.
265. Rottiers V., Naar A.M. MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell Biol. 2012, 13:239-250.
266. Bhathena J., Martoni C., Kulamarva A., Tomaro-Duchesneau C., Malhotra M., Paul A., Urbanska A.M., Prakash S. Oral probiotic microcapsule formulation ameliorates non-alcoholic fatty liver disease in Bio F1B Golden Syrian hamsters. PLoS One 2013, 8:e58394.